CIK 0000920148
- Large accelerated filer
LABCORP HOLDINGS INC.
Sign in to watch- Ticker
- LH
- Exchange
- NYSE
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 992588107
- Phone
- +1 336-229-1127
- Business address
- 358 S MAIN ST, BURLINGTON, NC, 27215
- Former names
- LABORATORY CORP OF AMERICA HOLDINGS, NATIONAL HEALTH LABORATORIES HOLDINGS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,377,699
- in 4 filings, $108K under 10b5-1 plans
Net −$1,377,699. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-08-08 | ANDERSON KERRII B Director | Sale | −5,000 | $211.57 | $1.1M | 15,275 |
| 2023-08-01 | Wilkinson Peter J SVP, Chief Accounting Officer | Exercise or conversion | +56 | 3,488.22 | ||
| 2023-08-01 | Wilkinson Peter J SVP, Chief Accounting Officer | Shares withheld for taxes | −17 | $213.61 | $4K | 3,471.22 |
| 2023-08-01 | Wilkinson Peter J SVP, Chief Accounting Officer | Exercise or conversion · Restricted Stock Unit | −56 | 3,858 | ||
| 2023-06-30 | van der Vaart Sandra D EVP, Chief Legal Officer | Grant or award · Restricted Stock Unit | +6,207 | 7,974 | ||
| 2023-06-30 | Wilkinson Peter J SVP, Chief Accounting Officer | Grant or award · Restricted Stock Unit | +3,104 | 3,851 | ||
| 2023-06-30 | Summy Amy B. EVP, Chief Marketing Officer | Grant or award · Restricted Stock Unit | +5,824 | 7,004 | ||
| 2023-06-30 | Schroeder Mark S EVP, Pres Diagnostics & COO | Grant or award · Restricted Stock Unit | +11,648 | 14,769 | ||
| 2023-06-30 | Schechter Adam H President & CEO | Grant or award · Restricted Stock Unit | +73,013 | 89,841 | ||
| 2023-06-30 | EISENBERG GLENN A Chief Financial Officer, EVP | Grant or award · Restricted Stock Unit | +20,193 | 33,957 | ||
| 2023-06-30 | DiVincenzo Jonathan P. EVP, Pres, Central Labs & Intl | Grant or award · Restricted Stock Unit | +3,036 | 4,700 | ||
| 2023-06-30 | Caveney Brian J EVP, Pres of ED, CMO & CSO | Grant or award · Restricted Stock Unit | +11,648 | 14,629 | ||
| 2023-06-30 | BERBERIAN LANCE EVP, CIO & CTO | Grant or award · Restricted Stock Unit | +7,758 | 9,585 | ||
| 2023-06-29 | van der Vaart Sandra D EVP, Chief Legal Officer | Sale 10b5-1 | −212 | $240.00 | $51K | 7,604.7 |
| 2023-06-06 | Rothman Paul Director | Grant or award · Restricted Stock Unit | +642 | 642 | ||
| 2023-05-19 | Kirchgraber Paul R CEO, Covance Drug Development | Exercise or conversion | +4,300 | $182.51 | $785K | 17,246 |
| 2023-05-19 | Kirchgraber Paul R CEO, Covance Drug Development | Sale | −4,300 | $216.91 | $933K | 12,946 |
| 2023-05-19 | Kirchgraber Paul R CEO, Covance Drug Development | Exercise or conversion · Non-qualified Stock Options | −4,300 | 0 | ||
| 2023-05-18 | Schroeder Mark S EVP, Pres Diagnostics & COO | Exercise or conversion 10b5-1 | +1,500 | $130.60 | $196K | 8,187.4 |
| 2023-05-18 | Schroeder Mark S EVP, Pres Diagnostics & COO | Sale 10b5-1 | −1,500 | $216.77 | $325K | 6,687.4 |
Page 36 of 41 · 816 trades